These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8943690)

  • 41. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
    Plumb JA; Gerritsen M; Workman P
    Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
    Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
    Verweij J; Wanders J; Nielsen AL; Pavlidis N; Calabresi F; ten Bokkel Huinink W; Bruntsch U; Piccart M; Franklin H; Kaye SB
    Ann Oncol; 1994 Apr; 5(4):375-6. PubMed ID: 8075039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
    Herait P; Rougier P; Oliveira J; Delgado FM; May-Levin F; Hayat M; Armand JP
    Invest New Drugs; 1988 Dec; 6(4):323-5. PubMed ID: 3229944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.
    Vainchtein LD; Rosing H; Mirejovsky D; Lenaz L; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2007 Jan; 43(1):285-92. PubMed ID: 16920321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase.
    Phillips RM
    Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
    Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A
    Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
    Begleiter A; Leith MK; Curphey TJ
    Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
    Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG
    J Clin Oncol; 1991 Aug; 9(8):1487-94. PubMed ID: 2072148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.
    Samuni AM; DeGraff W; Krishna MC; Mitchell JB
    Mol Cell Biochem; 2002; 234-235(1-2):327-33. PubMed ID: 12162451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.
    Hubbard KP; Pazdur R; Ajani JA; Braud E; Blaustein A; King M; Llenado-Lee M; Winn R; Levin B; Abbruzzese JL
    Am J Clin Oncol; 1992 Dec; 15(6):524-7. PubMed ID: 1449117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
    Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P
    Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.
    Phillips RM; Loadman PM; Cronin BP
    Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antineoplastic chemotherapy of digestive tumors].
    Espinosa Arranz E; Ordóñez Gallego A; González Barón M
    Med Clin (Barc); 1991 Mar; 96(12):471-4. PubMed ID: 2056788
    [No Abstract]   [Full Text] [Related]  

  • 55. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
    Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
    Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.
    Saunders MP; Jaffar M; Patterson AV; Nolan J; Naylor MA; Phillips RM; Harris AL; Stratford IJ
    Biochem Pharmacol; 2000 Apr; 59(8):993-6. PubMed ID: 10692564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
    Chung-Faye G; Palmer D; Anderson D; Clark J; Downes M; Baddeley J; Hussain S; Murray PI; Searle P; Seymour L; Harris PA; Ferry D; Kerr DJ
    Clin Cancer Res; 2001 Sep; 7(9):2662-8. PubMed ID: 11555577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
    Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
    Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.